Overview

Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

Status:
Completed

Trial end date:
2010-04-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate long-term safety and tolerability of Vortioxetine over a period of 52 weeks in patients with Major Depressive Disorder (MDD) having completed 8-week acute treatment.

Phase:

Phase 3

Details

Lead Sponsor:

H. Lundbeck A/S

Treatments:

Vortioxetine